Cancer research is a high priority for the DoD and especially for the VA.
The drug met the primary endpoint in a phase 3 study of maintenance therapy after stem cell transplant.
The results suggest that monitoring strategies should be studied.
Clinicians examine a patient who was once diagnosed with multiple myeloma but who actually had something else. ...
CHICAGO – Frontline use of chemoimmunotherapy is complicated.
CHICAGO – Fitzpatrick skin types I and II boost risk 7- to 9-fold.
The clinical trial is the first to demonstrate the activity of a JAK inhibitor in the treatment of myeloma patients.
The phase 1b/2 trial will begin enrollment in the second half of 2018.
This case highlights the appropriate use of genetic testing and supports expanding the clinical diagnosis of multiple endocrine neoplasia type 1...
New analytic tools and data use genetic signatures to help researchers distinguish the differences among various cancers.